NovoCure Q1 Net Loss Doubles to $71M, EPS ($0.62), Despite 12% Revenue Jump
NVCR sits 26% above its 52-week low of $9.82.
Summary
NovoCure Ltd reported first-quarter 2026 results showing a significant deterioration in profitability, with net loss more than doubling to $71.14 million and diluted EPS loss widening to ($0.62) from ($0.31) year-over-year. This comes despite a 12.3% increase in revenue to $174.06 million, driven by international patient growth and product expansion including the U.S. launch of Optune Pax. While the company also highlighted positive Phase 3 METIS and Phase 2 PANOVA-4 clinical trial results, the substantial increase in losses is a material negative that will likely overshadow the revenue growth and clinical momentum for investors. Traders will be watching for signs of improved cost management and whether future revenue growth can mitigate these widening losses.
At the time of this announcement, NVCR was trading at $12.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.82 to $20.06. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.